Please assess the completion status of the following clinical trial:

Trial Title: Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients 12 years and older~* Diagnosis of M. abscessus, including all subspecies, abscessus, bolleti, and massiliense lung disease according to the 2007 ATS/IDSA criteria~* Both newly diagnosed and currently on treatment or previously treated patients will be included~* Culture positive (either sputum or bronchoscopy) for M. abscessus at time of screening~* Willingness to adhere to a treatment regimen, study visits, and study procedures during the course of the study.~* Ability to produce at approximately 3.0 mL of sputum or be willing to undergo an induction that produces approximately 3.0 mL of sputum for culture collection~* Female of childbearing potential agrees to practice an acceptable method of birth control (e.g., abstinence, hormonal or barrier methods, partner sterilization, or IUD)~* Written informed consent or assent obtained from the patient, parent or legal guardian prior to the performance of any study related procedures~Exclusion Criteria:~* Active pulmonary tuberculosis requiring treatment at screening~* Treatment with inhaled or intravenous Amikacin within 14 days prior to baseline~* Known hypersensitivity to aminoglycosides~* Aspartate aminotransferase or alanine aminotransferase ≥ 3 times the upper limit of normal or total bilirubin ≥ 2 times the upper limit of normal (ULN) at screening~* Current addiction to alcohol or illicit drug abuse~* Any condition which in the opinion of the Investigator interferes with ability to adhere to study requirements~* Primary immunodeficiency syndromes and acquired immunodeficiency syndromes (e.g., HIV-positive patients regardless of CD4 counts)~* Absolute neutrophil count ≤500/μL at Screening~* Significant (as determined by the investigator) hearing loss, vestibular dysfunction, neuromuscular weakness or a diagnosis of myasthenia gravis, where the potential risk of aminoglycoside toxicity outweighs the potential benefit~* Serum creatinine \>2 times ULN at Screening~* History of lung transplantation~* Any condition that, in the judgment of the Investigator, would compromise the ability of the subject to complete the study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LAI plus multi-drug regimen (Type: EXPERIMENTAL): once daily dosing of Liposomal-Amikacin for Inhalation (LAI) 590 mg for 12 months plus standard of care (SOC) mycobacterial multi-drug regimen in accordance with the 2007 ATS/ IDSA guidelines

Based on this trial design, predict the completion outcome and termination type (if applicable).